JP2013511560A - チロシンキナーゼインヒビターに対する感受性を増加する方法と組成物 - Google Patents

チロシンキナーゼインヒビターに対する感受性を増加する方法と組成物 Download PDF

Info

Publication number
JP2013511560A
JP2013511560A JP2012540229A JP2012540229A JP2013511560A JP 2013511560 A JP2013511560 A JP 2013511560A JP 2012540229 A JP2012540229 A JP 2012540229A JP 2012540229 A JP2012540229 A JP 2012540229A JP 2013511560 A JP2013511560 A JP 2013511560A
Authority
JP
Japan
Prior art keywords
egfr
mirna
mir
cancer
tyrosine kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012540229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013511560A5 (enExample
Inventor
ジェフリー リードマン，ピーター
マイケル ジャイルズ，キース
カリス カリノウスキ，フェリシティー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Western Australia
Original Assignee
University of Western Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009905758A external-priority patent/AU2009905758A0/en
Application filed by University of Western Australia filed Critical University of Western Australia
Publication of JP2013511560A publication Critical patent/JP2013511560A/ja
Publication of JP2013511560A5 publication Critical patent/JP2013511560A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012540229A 2009-11-24 2010-11-24 チロシンキナーゼインヒビターに対する感受性を増加する方法と組成物 Pending JP2013511560A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2009905758 2009-11-24
AU2009905758A AU2009905758A0 (en) 2009-11-24 Method of Modulating Epidermal Growth Factor (EGF) Ligands
PCT/AU2010/001578 WO2011063456A1 (en) 2009-11-24 2010-11-24 Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2013511560A true JP2013511560A (ja) 2013-04-04
JP2013511560A5 JP2013511560A5 (enExample) 2014-01-16

Family

ID=44065735

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012540229A Pending JP2013511560A (ja) 2009-11-24 2010-11-24 チロシンキナーゼインヒビターに対する感受性を増加する方法と組成物
JP2012540228A Pending JP2013511559A (ja) 2009-11-24 2010-11-24 上皮成長因子受容体リガンドのモジュレーション

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012540228A Pending JP2013511559A (ja) 2009-11-24 2010-11-24 上皮成長因子受容体リガンドのモジュレーション

Country Status (9)

Country Link
US (2) US20130090366A1 (enExample)
EP (2) EP2521555B1 (enExample)
JP (2) JP2013511560A (enExample)
CN (2) CN102762214A (enExample)
AU (2) AU2010324530B2 (enExample)
CA (2) CA2781571A1 (enExample)
DK (1) DK2521555T3 (enExample)
ES (1) ES2608923T3 (enExample)
WO (2) WO2011063455A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2503765T3 (es) 2004-11-12 2014-10-07 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
AU2011274619B2 (en) * 2010-07-06 2016-11-10 Interna Technologies Bv miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
JP6342329B2 (ja) * 2011-11-25 2018-06-13 アンテグラジャンＩｎｔｅｇｒａｇｅｎ Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法
FR2984168B1 (fr) * 2011-12-19 2019-07-05 Chanel Parfums Beaute Micro-rna pour leur utilisation dans la pigmentation
WO2013173500A2 (en) * 2012-05-15 2013-11-21 New York University Method for predicting recurrence of melanoma using mirna alterations
EP2908830A4 (en) * 2012-10-18 2016-11-30 Univ Western Australia CANCER THERAPY WITH MIRNAS
US20140308274A1 (en) * 2013-03-15 2014-10-16 Mirna Therapeutics, Inc. Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors
US20140309278A1 (en) * 2013-03-15 2014-10-16 Mirna Therapeutics, Inc. Combination cancer treatments utilizing micrornas and egfr-tki inhibitors
EP3027225B1 (en) 2013-07-31 2021-03-24 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using transforming growth factor alpha
CN108537001B (zh) * 2018-04-12 2021-06-01 华中科技大学鄂州工业技术研究院 一种预测用于治疗肝癌的特异性治疗药物的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025073A1 (en) * 2006-08-28 2008-03-06 The University Of Western Australia Method of modulation of expression of epidermal growth factor receptor (egfr) involving mirna
WO2008089388A2 (en) * 2007-01-19 2008-07-24 Bayer Healthcare Llc Treatment of cancers having resistance to chemotherapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2583375C (en) * 2004-09-02 2013-01-15 Yale University Regulation of oncogenes by micrornas
ES2503765T3 (es) * 2004-11-12 2014-10-07 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
CN101675165A (zh) * 2006-12-08 2010-03-17 奥斯瑞根公司 Let-7微小rna的功能和靶标

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025073A1 (en) * 2006-08-28 2008-03-06 The University Of Western Australia Method of modulation of expression of epidermal growth factor receptor (egfr) involving mirna
WO2008089388A2 (en) * 2007-01-19 2008-07-24 Bayer Healthcare Llc Treatment of cancers having resistance to chemotherapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014043279; Ｒａｉ，　Ｋ．　ｅｔ　ａｌ．: １００ｔｈ　ＡＡＣＲ　Ａｎｎｕａｌ　Ｍｅｅｔｉｎｇ　Ａｂｓｔｒａｃｔｓ , 200904, Ａｂｓｔｒａｃｔ　＃１３９６ *

Also Published As

Publication number Publication date
JP2013511559A (ja) 2013-04-04
EP2504014A4 (en) 2013-04-17
CA2781572A1 (en) 2011-06-03
EP2521555A1 (en) 2012-11-14
US9051551B2 (en) 2015-06-09
CA2781571A1 (en) 2011-06-03
US20130116299A1 (en) 2013-05-09
AU2010324530B2 (en) 2016-12-15
CN102762214A (zh) 2012-10-31
EP2521555A4 (en) 2013-08-07
DK2521555T3 (en) 2017-01-09
EP2521555B1 (en) 2016-09-28
WO2011063455A1 (en) 2011-06-03
CN102762213A (zh) 2012-10-31
AU2010324529A1 (en) 2012-07-19
EP2504014A1 (en) 2012-10-03
WO2011063456A1 (en) 2011-06-03
ES2608923T3 (es) 2017-04-17
US20130090366A1 (en) 2013-04-11
AU2010324530A1 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
US9051551B2 (en) Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors
US9675633B2 (en) miRNA for treating cancer and for use with adoptive immunotherapies
JP5976643B2 (ja) 二本鎖ｒｎａによるベータ−カテニンの特異的阻害に対する方法と組成物
CN104994861B (zh) 使用miRNA的癌症疗法
WO2014046617A1 (en) Compositions and methods for treating cancer
US20190300882A1 (en) Methods of treating neuroblastoma and reagents therefor
WO2013066721A2 (en) Methods and compositions for the specific inhibition of met by double-stranded rna
WO2013048345A1 (en) Methods and pharmaceutical compositions for treating cancer
IL277136A (en) Means and methods for lowering the tumorigenicity of cancer stem cells
CA2889020A1 (en) Treatment of metastatic breast cancer
EP2654801B1 (en) Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138
WO2010032506A1 (ja) アレルギー疾患の治療のための核酸医薬
D'Andrea GENETIC AND FUNCTIONAL DISSECTION OF THE MIR-17-92 CLUSTER OF MIRNAS
WO2022081693A1 (en) Compositions and methods targeting circ2082 for the treatment of cancer
WO2008052238A1 (en) Treatment of urological cancer
WO2018088426A1 (ja) 抗癌剤及びその使用
Maritz Repression of telomerase components in isogenic normal, immortal and tumorigenic cells
Huang The Role of HuR in Mediating Ovarian Cancer Treatment

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20130321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150421

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151006